Corona Remedies Limited · NSE:CORONA
Corona Remedies — Investor Presentation (January 2026)
33 slides from Corona Remedies's investor presentation, Jan 3, 2026
Slide 1: Exchange filing cover letter for analyst/investor presentation
January 03, 2026 To, To, Listing Operation Department Listing Compliance Department BSE Limited National Stock Exchange of India Limited P. J. Towers, Exchange Plaza, Bandra Kurla Dalal Street, Mumbai - 400001 Complex, Bandra (East), Mumbai– 400051 (Scrip Code: 544644) (SYMBOL: CORONA) Dear Sir / Ma
Slide 2: CORONA Remedies Limited Investor Presentation: January 2026
CORONA Remedies Limited Investor Presentation: January 2026
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by CORONA Remedies Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any secur
Slide 4: Contents
Contents About us Overview of CORONA Focused Brand Building Approach Strong brand recall across Therapeutic Areas CORONA : Outpacing IPM Growth CORONA vs. IPM Road Ahead Key Growth Strategies Operational & Financial Performance Financial & Operational Performance for Q2 and H1 FY26 Annexures Histori
Slide 5: CORONA Remedies at a Glance
CORONA Remedies at a Glance 16.8% Jumped 8 ranks Revenue CAGR 1 96.3% 70.1% in 3 years Revenue from India Chronic portfolio Over MAT Jun-22 to Business contribution 1.82x growth MAT Jun-25 compared to IPM 1 EU-GMP & #6 in Women’s Healthcare WH0-GMP 71 Brands with #5 in Pain Management approved Gujar
Slide 6: Journey over the years
Journey over the years ❖ In -licensing arrangement with Ferring ❖ Launch of 1st cardiological Pharmaceuticals Private Limited to ❖ Acquisition of 7 brands from ❖ Founded in 2004 and division: Wellness market certain products under women’s Bayer Zydus Pharma Ltd launch of first division, ❖ Purchased
Slide 7: CORONA's 3C Philosophy
CORONA’s 3C Philosophy Culture • Ruthless Execution • Internal Promotion • Adaptability • Humbleness Courage CORONA’s • Accepting Mistakes 3C and improving • Robust Inorganic Philosophy Opportunities Commitment • Global Quality Products • Value Creation for Stakeholders • Long Term Sustainable Growt
Slide 8: Quality Focused State of the Art Manufacturing Facilities
Quality Focused State of the Art Manufacturing Facilities Himachal Pradesh Total Installed Capacity Gujarat Installed capacity of ~403 Mn tablets/capsules & 10 Mn liquid Installed capacity of ~1.25 bottles Bn* tablets/capsules & 20 Formulations* WHO-GMP & Uganda NDA Mn sachets certifications Certifi
Slide 9: Professional Senior Management Leading the Way
Professional Senior Management Leading the Way Niravkumar Kritikumar Mehta Ankur Kritikumar Mehta Viral Bhupendrabhai Sitwala Managing Director & CEO Joint Managing Director Whole-Time Director Over 2 decades of experience in the Over 2 decades of experience in the Over 2 decades of experience in th
Slide 10: Experienced Board of Directors
Experienced Board of Directors Niravkumar Kritikumar Mehta Ankur Kritikumar Mehta Viral Bhupendrabhai Sitwala Dr. Kiritkumar Laxmidas Mehta Managing Director & CEO Joint Managing Director Whole-Time Director Chairman and Non-Executive Director Ameetkumar Hiranyakumar Desai Monica Kanuga Shirish Gund
Slide 11: ESG @ CORONA Remedies
ESG @ CORONA Remedies • Existing solar power plant of 1.3 MW at Bhayla Plant and investment for 4.25 MW in upcoming E Solar Park Spread across 11.9 Acres which will save significant electricity cost • Protection of Environment by Tree Plantation, Distribution of Plant Saplings, initiatives like wear
Slide 12: Contents
Contents About us Overview of CORONA Focused Brand Building Approach Strong brand recall across Therapeutic Areas CORONA : Outpacing IPM Growth CORONA vs. IPM Road Ahead Key Growth Strategies Operational & Financial Performance Financial & Operational Performance for Q2 and H1 FY26 Annexures Histori
Slide 13: Engine Brands approach with Successful Scaling Up of Brands
“Engine” Brands approach with Successful Scaling Up of Brands 27 Engine Brands Established track record of building and scaling brands Brands with Sales ~72% 29 >INR 10 Crs 38 Contribution to Domestic Sales over MAT Jun-22 to MAT Jun-25 1 6 ~21% CAGR over 0 1 MAT Jun-22 to MAT Jun-25 7 No. of Brands
Slide 14: Acquisition & Strategic Collaborations for India Business
Acquisition & Strategic Collaborations for India Business Significantly scaled-up acquired brands Strategic collaborations for India Business Sr. No Acquired From Brands Ferring Pharmaceuticals, Switzerland Thyrocab 1 ABBOTT India Limited In-Licensing Arrangement for certain products in Obimet Women
Slide 15: Strategic Portfolio Diversification & Brand Development
Strategic Portfolio Diversification & Brand Development 12.4% 13.5% West Geography South Expanding and diversifying Wise 21.5% 48.0% 20.2% 46.3% FY23 FY25 North geographical presence to strengthen East and deepen pan-India penetration 18.0% 20.0% Therapy Wise 27.5% Women’s Healthcare 29.3% 42.3% 34.
Slide 16: Contents
Contents About us Overview of CORONA Focused Brand Building Approach Strong brand recall across Therapeutic Areas CORONA : Outpacing IPM Growth CORONA vs. IPM Road Ahead Key Growth Strategies Operational & Financial Performance Financial & Operational Performance for Q2 and H1 FY26 Annexures Histori
Slide 17: Indian Pharmaceutical Market: High-Growth Landscape
Indian Pharmaceutical Market : High-Growth Landscape IPM is poised to grow at CAGR of 8-9% till FY30 Growth drivers for domestic formulations industry INR Trillion 3.1 2.3 Improving life expectancy and changing 2.1 1.8 1.9 demographic profile 1.5 1.5 01 Rising prevalence of chronic diseases FY20 FY2
Slide 18: CORONA Remedies: Demonstrated 1.82x Growth compared to IPM
CORONA Remedies: Demonstrated 1.82x Growth compared to IPM CORONA has grown at 1.82x compared to IPM growth[1] Growth driven by volume, price and new product launches 16.8% 6.6% IPM CORONA 5.7% 5.3% 4.6% 9.2% 2.2% 1.7% Average yearly Average yearly Average yearly CORONA Remedies IPM Average volume g
Slide 19: Cementing position in Chronic segment with focus on Key Therapies
Cementing position in Chronic segment with focus on Key Therapies Women’s Healthcare Cardio-Diabeto Pain Management Urology CORONA Remedies vis-à-vis 2.27x 2.25x 1.56x 3.56x IPM CAGR[2] 20.7% 22.0% 19.2% 59.6% 12.3% 9.1% 9.7% 16.8% IPM CORONA IPM CORONA IPM CORONA IPM CORONA Women’s Healthcare Cardi
Slide 20: Contents
Contents About us Overview of CORONA Focused Brand Building Approach Strong brand recall across Therapeutic Areas CORONA : Outpacing IPM Growth CORONA vs. IPM Road Ahead Key Growth Strategies Operational & Financial Performance Financial & Operational Performance for Q2 and H1 FY26 Annexures Histori
Slide 21: Future Growth Strategies
CORONA Remedies Limited Future Growth Strategies • Improve MR productivity, expanding prescriber base and increasing the number of products Increase market share 1 within the domestic IPM prescribed per prescriber • Intensify engagement with super-specialist prescribers in metro, semi-metro, and urb
Slide 22: Contents
Contents About us Overview of CORONA Focused Brand Building Approach Strong brand recall across Therapeutic Areas CORONA : Outpacing IPM Growth CORONA vs. IPM Road Ahead Key Growth Strategies Operational & Financial Performance Financial & Operational Performance for Q2 and H1 FY26 Annexures Histori
Slide 23: Financial Highlights – Q2 & H1FY26
Financial Highlights – Q2 & H1FY26 Revenue (INR Crores) EBITDA (INR Crores) PAT (INR Crores) 17.0% 27.4% 35.1% 707.7 148.3 98.5 605.0 116.3 72.9 15.1% 17.4% 21.8% 361.1 78.5 52.3 313.9 66.8 43.0 Q2FY25 Q2FY26 H1FY25 H1FY26 Q2FY25 Q2FY26 H1FY25 H1FY26 Q2FY25 Q2FY26 H1FY25 H1FY26 EBITDA Margin (%) PAT
Slide 24: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Profit and Loss (INR Crores) Q2FY26 Q2FY25 Y-o-Y H1FY26 H1FY25 Y-o-Y Revenue from Operations 361.1 313.9 15.1% 707.7 605.0 17.0% Cost of Goods Sold 68.7 62.6 134.4 124.5 Gross Profit 292.5 251.3 573.2 480.6 Gross Margin (%) 81.0% 80.1% 81.0% 79.4% Employee Cost 1
Slide 25: Consolidated Balance Sheet
Consolidated Balance Sheet Assets (INR Crores) Sep-25 Mar-25 Equity & Liabilities (INR Crores) Sep-25 Mar-25 Non - Current Assets 630.8 591.0 Total Equity 659.7 606.3 Property, plant and equipment 200.1 198.7 Share Capital 61.2 61.2 Capital work-in-progress 204.8 186.0 Other Equity 598.5 545.2 Intan
Slide 26: Abridged Consolidated Cash Flow Statement
Abridged Consolidated Cash Flow Statement Particulars (INR Crores) H1FY26 H1FY25 Net Profit Before Tax 130.5 96.6 Adjustments for: Non -Cash Items / Other Investment or Financial Items 23.3 24.3 Operating profit before working capital changes 153.8 120.9 Changes in working capital (17.7) (0.5) Cash
Slide 27: Contents
Contents About us Overview of CORONA Focused Brand Building Approach Strong brand recall across Therapeutic Areas CORONA : Outpacing IPM Growth CORONA vs. IPM Road Ahead Key Growth Strategies Operational & Financial Performance Financial & Operational Performance for Q2 and H1 FY26 Annexures Histori
Slide 28: Historical Consolidated Profit & Loss Statement
Historical Consolidated Profit & Loss Statement Profit and Loss (INR Crores) FY25 FY24 FY23 Revenue from Operations 1,196.4 1,014.5 884.1 Cost of Goods Sold 236.5 226.8 211.0 Gross Profit 959.9 787.6 673.1 Gross Margin (%) 80.2% 77.6% 76.1% Employee Cost 346.1 295.4 254.8 Other Expenses 373.8 337.5
Slide 29: Historical Consolidated Balance Sheet
Historical Consolidated Balance Sheet Assets (INR Crores) Mar-25 Mar-24 Mar-23 Equity & Liabilities (INR Crores) Mar-25 Mar-24 Mar-23 Non - Current Assets 591.0 540.7 303.5 Total Equity 606.3 480.4 408.5 Property, plant and equipment 198.7 191.0 184.1 Share Capital 61.2 61.2 61.2 Capital work-in-pro
Slide 30: Historical Consolidated Abridged Cash Flow Statement
Historical Consolidated Abridged Cash Flow Statement Particulars (INR Crores) FY25 FY24 FY23 Net Profit Before Tax 198.5 118.5 110.9 Adjustments for: Non -Cash Items / Other Investment or Financial Items 52.3 46.9 22.6 Operating profit before working capital changes 250.8 165.3 133.4 Changes in work
Slide 31: Historical Financial Statement
Historical Financial Statement Revenue (INR Crores) EBITDA (INR Crores) PAT (INR Crores) 1,196.4 240.0 149.4 1,014.5 884.1 154.7 148.3 98.5 707.7 84.9 90.5 128.0 FY23 FY24 FY25 H1FY26 FY23 FY24 FY25 H1FY26 FY23 FY24 FY25 H1FY26 EBITDA Margin (%) PAT Margin (%) 20.1% 20.9% 13.9% 12.5% 14.5% 15.3% 9.6
Slide 32: Historical Financial Ratios
Historical Financial Ratios ROCE (%) ROE (%) 49.7% 31.1% 27.5% 41.3% 23.3% 31.2% 20.4% 28.4% FY23 FY24 FY25 H1FY26* FY23 FY24 FY25 H1FY26* OCF/EBITDA (%) Net working Capital Days 101.3% 31 80.2% 79.4% 76.5% 23 24 23 FY23 FY24 FY25 H1FY26 FY23 FY24 FY25 H1FY26 *ROE and ROCE for H1FY26 is annualised 3
Slide 33: Thank You
THANK YOU For further information, please contact: CORONA Remedies Limited Strategic Growth Advisors Private Limited (SGA) CIN: L24231GJ2004PLC044656 CIN: U74140MH2010PTC204285 Ms. Chetna Dharajiya – Company Secretary & Compliance Officer Mr. Sagar Shroff / Mr. Tanay Shah sagar.shroff@sgapl.net / ta
CORONA Remedies — Investor Presentation (January 2026) on 6ix